



A patient-friendly approach to improved cancer care

Programme Presentation 2026



Disclaimer

THIS PRESENTATION AND ANY OTHER INFORMATION DISCUSSED AT THE PRESENTATION (THE "PRESENTATION") IS BEING PROVIDED TO YOU SOLELY FOR YOUR INFORMATION. THIS PRESENTATION, WHICH HAS BEEN PREPARED AND IS ISSUED BY VASODYNAMICS LIMITED (THE "ISSUER"), IS PRELIMINARY IN NATURE, BASED ON MANAGEMENT BELIEFS AND IS SUBJECT TO UPDATING, REVISION AND AMENDMENT. THIS PRESENTATION MAY NOT BE REPRODUCED IN ANY FORM, FURTHER DISTRIBUTED OR PASSED ON, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON, OR PUBLISHED, IN WHOLE OR IN PART, FOR ANY PURPOSE. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF APPLICABLE SECURITIES LAWS.

Information and opinions contained in this Presentation are provided as at the date of the Presentation, are subject to change without notice and do not purport to contain all information that may be required to evaluate the Issuer. The information in this presentation is in draft form and has not been independently verified. The information in this Presentation does not constitute and may not be relied upon in any manner as legal, tax, investment, accounting, regulatory or other advice whatsoever. You should seek independent and professional advice and conduct an independent investigation and analysis of the information in this Presentation, as well as all public information on the Issuer and any shares, securities or financial instruments of the Issuer (the "Securities"). This Presentation contains forward-looking statements (*i.e.* any statements other than statements regarding historical facts or present facts or circumstances) that reflect the Issuer's management's current views with respect to future events and performance of the Issuer. Forward-looking statements are subject to changing circumstances and should, although the Issuer believes they are reasonable, not be relied upon to materialize or prove to be correct. Actual results or outcome could differ materially from those set out in the forward-looking statements. Certain forward-looking statements may be indicated by the context in which they are made or with words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or similar expressions, or their negative. Certain market and competitive position data contained in this Presentation has been obtained from published and non-published industry publications or reports conducted by third parties. The Issuer has not verified and cannot give any assurances as to the accuracy of such information and the accuracy and completeness of such information is not guaranteed. Certain statements in this Presentation are based on the internal analyses of the Issuer, which may involve assumptions and estimates based on the knowledge and experience of its management. Such observations are not reviewed or verified by any external sources.

Neither the Issuer, nor any of their respective partners, directors, officers, employees, advisers, affiliates, representatives or agents undertake or is under any duty or obligation to update or revise this Presentation or to correct any inaccuracies in any such information which may become apparent or to provide you with any additional information or otherwise inform you should any information in this Presentation prove inaccurate, incomplete or, with regards to forward-looking statements, not materialize and disclaim any obligation to do so. None of the foregoing persons accept any responsibility whatsoever for the contents of this Presentation and no representation or warranty, expressed or implied, is made by any such person in relation to the contents of this Presentation, and no reliance should be placed on fairness, accuracy or completeness of the information and opinions contained in this Presentation. The foregoing persons expressly disclaim, to the maximum extent permitted by law, any and all liability, whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in connection with the accuracy or completeness of the information or for any of the opinions contained herein (including forward-looking information, information based on publications or reports by third parties and information based on internal analyses of the Issuer), or any other written or oral information made available in connection with this Presentation, or for any errors, omissions or misstatements contained in this Presentation or such other information. None of the foregoing persons shall have any liability whatsoever (in negligence or otherwise) for any direct, indirect or consequential loss, damages, costs or prejudices whatsoever arising from the use of this Presentation or its contents or otherwise arising in connection with this Presentation.

By attending a meeting where this Presentation is made, by otherwise accessing the Presentation or by signing an agreement to underwrite the Securities you warrant, represent, undertake and acknowledge that: (i) you have read and agreed to comply with the foregoing limitations and restrictions, and (ii) you are able to receive this Presentation without contravention of any applicable legal and regulatory restrictions and you understand the sanctions attached to the misuse, disclosure or improper circulation of the Presentation.

Company Overview



Novel Technology



Proven Science



Large Market Opportunity

- We are based in Stevenage Bioscience Catalyst (SBC) and developing medicines that **prevent debilitating side-effects** associated with cancer chemo / radiotherapies such as oral mucositis, dermatitis and alopecia so to enhance the clinical outcomes of the anticancer therapeutics
- Our **platform** utilises existing proven vasoconstrictor molecules in novel formulations for a faster protection only to normal mucosa/skin/hair, low-risk development approach, offer attractive partnership potentials for oncology therapeutics
- Compelling pre-clinical data and **positive early clinical results** indicate **35% reduction in severity of radiodermatitis** and **up to 49% reduction in radiation-induced oral mucositis**, support moving pipeline programs into future clinical trials;
- Our experienced **leadership members** work in drug development, clinical trial management, regulatory affairs, pharmaceutical distribution and manufacturing
- We are actively seeking partnerships to support **global multi-centre Phase 2-3 trials and market access**

Backed by:



Good Ventures



LONGEVITY
TECH.FUND

A scanning electron micrograph (SEM) showing several cancer cells. The cells are spherical with a highly textured, bumpy surface. Some cells are connected by thin, fibrous structures. The background is dark, making the cells stand out.

The Problem

Cancer chemotherapy and
radiotherapy side-effects

The Problem

Patients undergoing cancer treatment suffer from debilitating side effects

These include elements such as skin damage and hair loss, causing missed treatments, treatment cessation and potentially reduced cancer control, presenting a large unmet medical need and impact on healthcare system costs.




Radiotherapy Induced Oral Mucositis (RIOM)

80% **\$17k**

Of head and neck cancer patients experience oral mucositis

Average healthcare costs /patient



Radiodermatitis (RD)

50% **Up to 87%**

Of all cancer patients experience radiodermatitis

Of breast cancer patients experience radiodermatitis



Chemo-Induced Alopecia (CIA)




33% **38%**

Of cancer patients experience CIA on average

Of post-menopausal breast cancer patients reported permanent CIA

The Market

There are very limited options for preventative treatment available on the market

Condition	Approved preventative drugs	Approved preventative devices
 <p>Radiotherapy-induced Oral Mucositis (RIOM)</p>	<p>Palifermin (Kepivance) approved only for blood cancers receiving high dose chemotherapy and radiotherapy prior to bone marrow transplantation</p> <p>Caphosol (OTC) Mouth wash required to be taken 4x per day with very limited efficacy in real world setting</p>	<p>Low level laser therapy (LLLT) Stimulates wound healing and reduces inflammation, material staff time required for administration</p>
 <p>Radiodermatitis</p>	<p>No approved preventative drugs</p>	<p>StrataXRT (and others) OTC medical film to promote moisture and healing, no RCT evidence and lack of broad uptake</p>
 <p>Chemo-induced Alopecia (CIA)</p>	<p>No approved preventative drugs</p>	<p>Cold Caps FDA approved Medical Device. Patient cost approx. £3,500 per course. Limited uptake due to pain. Concerns over metastasis stimulation (Dignitana AB, Paxman Coolers, Penguin Cold Caps, Arctic Cold Caps, Wishcaps and Warrior Caps)</p>

Our Technology

A preventative, topical solution



What We Do

We developed novel medicines to prevent and alleviate the debilitating side-effects of cancer therapies



Muc1 (NG11-2)

Treats:

Radiotherapy-induced Oral
Mucositis (**RIOM**)

Application:

Oral topical mouth rinse solution
once usage



Derm1 (NG12-1)

Treats:

Radiodermatitis
(**RD**)

Application:

Dermal topical sprayable solution
with spray applicator



Derm2 (NG13-2)

Treats:


Chemotherapy-induced Alopecia
(**CIA**)

Application:


Scalp topical balm solution
with comb applicator

Mechanism of Action

Prophylactic vasoconstriction to reduce/eliminate the causal origin of inflammation



Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients who have cancer. Dent Clin North Am. 2008 Jan;52(1):61-77, viii. doi: 10.1016/j.cden.2007.10.002 . PMID: 18154865; PMCID: PMC2266835.




Mechanism of Action


Transient Topical Vasoconstriction with pharmaceutical protection to normal tissue only

1) Prevent ROS production and its damage to normal tissue

- a. By inducing vasoconstriction in normal tissue, minimise stem cell exposure to cytotoxic drugs, and reduce radiation-related Reactive Oxygen Species (ROS) surrounding the normal basal stem cells




- b. Lower blood supply reduces the production of ROS in normal tissue during radiotherapy, minimising ROS-related DNA damage in stem cells, and reduces inflammation mediated by cytokines and chemokines



2) Prevent normal stem cells progressing to apoptosis


- a. Vasoconstriction in normal skin/mucosa leads to a hypoxic environment, causing dividing basal cells to switch through their cell cycle and enter G₀ "sleeping mode", protecting vulnerable proliferating mucosal basal stem cells from radiation/chemo-damage.



- b. Accelerated healing when undamaged basal cells re-enter into the divisional cycle post treatment


3) No vasoconstriction and no cell cycle impact in cancerous tissue, enhancing chemo-exposure and radiotherapy effects

- a. Cancerous vasculature lacks intact smooth muscle in the blood vessel walls, so it cannot vasoconstrict, even when exposed to an α₁ agonist, maximising the effect of chemo/radiotherapy



Our Products

Data shows that our novel products alleviate the debilitating side-effects of cancer therapies



NG11-2 in Radiation-Induced Oral Mucositis (RIOM)

100% prevention of RIOM on hamster oral mucosa with positive dose dependence



NG12-1 in Radiodermatitis (RD)

100% prevention of RD on rat skin with positive dose dependence



Naive Chemo alone NG13-2 (low dose) prior Chemo NG13-2 (high dose) prior Chemo

NG13 in Chemo-induced Alopecia (CIA)

100% protection against CIA in mice with linear dose-response

Our Products

Results from data are very promising



Therapeutic products at clinical stages



Mouth Rinse

Oral Topical



Spray Solution

Dermal Topical



Solution (Balm)


Scalp Topical

Products & Indications	Muc1 (NG11-2) Prevent Radiation-Induced Oral Mucositis (RIOM)	Derm1 (NG12-1) Prevent Radiation dermatitis (RD)	Derm2 (NG13-2) Prevent Chemo-Induced Alopecia (CIA)
Target patient group (addressable populations in 2030)	Head & neck cancer (US 58K / EU137K / Global 880K)	Radiotherapy patients (US 1M / EU 1.5M / Global 8M)	Chemotherapy patients (US 600K / EU 940K / Global 5M)
Development Status	Phase-1b trial (UK) successful , preparing Phase 2/3 trial with commercial scale manufacturing	IIT Phase-2a successful , launching 'Named Patient Supply Programme', Out-licensing for Phase 3 and commercialisation in progress	Pre-clinical POC completed Preparing Phase2/3 trial with scalable manufacturing


Our products

Products positioned to optimise cancer patient care

😊 Cancer care pathway with VasoDynamics' products



☹ Cancer care pathway without VasoDynamics' products



Benefit to patients, reduce burden to healthcare providers & healthcare systems

1

Improved cancer therapy tolerance

Leads to:

- ✓ Greater patient compliance

2

Better patient quality of life

Leads to:

- ✓ Greater patient acceptability

3

Fewer hospitalisations

Leads to:

- ✓ A reduction in healthcare systems burden
- ✓ Healthcare supplier cost savings

4

Fewer dose reduction/delays

Leads to:

- ✓ Improved duration of therapy
- ✓ Payor/pricing leverage

Potential to **improve** key clinical outcomes

Positive Clinical Trial Results To-Date

Derm1 (NG12-1)

Radiodermatitis

Phase 1/1b in USA
Completed
with no safety finding

Phase 2a (IIT)
N=9, Breast Pts NG12-1
Thirty daily treatments, dermal
topically applied minutes before
radiotherapy, were well tolerated and
representing a mean **35% reductions**
in radiodermatitis severity with
statistical significance (P = 0.022).
<https://pubmed.ncbi.nlm.nih.gov/29273054/>

Derm2 (NG13-2)

Chemotherapy-induced
Alopecia

Phase 1
(shared data with Derm1 and Muc2);
Phase-1b study in USA
N=3, H&N Pts, NG13-1
Thirty daily treatments, scalp topically
applied,
no serious adverse events, and no evidence
for increased drug substance plasma levels
secondary to transdermal absorption.
Internal Report PC5

Phase 2-3 Pivotal
MHRA SA confirmed UK-AUS Pivotal trial
protocol and MA approach,
Trial preparation ongoing

Muc1 (NG11-2)

Radiation-induced Oral
Mucositis

Phase-1b study in UK
N=15, H&N Pts, NG11-2
30-35 daily mouth rinse, before
radiotherapy,
were **well tolerated** and representing
preliminary **40-49% reduction** of the
incidence of severe RIOM comparing
to the control groups reported in the
literature.
<https://www.isrctn.com/ISRCTN87831050>

Phase 2-3 Pivotal
MHRA, MEB confirmed global trial protocol,
EMA-FDA PSA ongoing

Our Products – IP and FTO

Strong intellectual property protection and full FTO

Patents Matrix

- Exclusive license of existing global patent from Wisconsin University (WARF) to enable global **Freedom-To-Operate fully**
- In-house new patent on indication, formulation and manufacturing global PCT filed in Oct 2022, entering EU, US, Japan, China, Israel etc 9 countries & regions in 2024, **expires in 2042**
- New clinical trial design and patient group selection patent global PCT filed in Oct 2023

Market and Data Protection

- UK-EU-US authorities may issue up to **10 years** of market exclusivity and **8 years** of data exclusivity to supply market protection to drugs like Muc1, Derm1 and Derm2
- Potential paediatric extension (505A/PUMA)

Development Pipelines



Development pipeline and focus

2026				2027		2028		2029	
Q1	Q2	Q3	Q4	H1	H2	H1	H2	H1	H2

Derm1 (NG12-1) for RD (Regional licensing)

Manufacturing
development &
production

Phase 3 trial and MA filing when licensing funds available;
Named Patient Supply Programme (NPSP) for RWD collection

Derm2 (NG13-2) for CIA (co-trial collaboration)

★ CTA/IND approval

★ Filing for approval

CTA filing

Pivotal Phase 2-3 trial (220 patients)

Manufacturing for trial supply,
scale-up for commercial supply

MA Filing

Muc1 (NG11-2) for RIOM (co-trial collaboration)

Advisory
meeting EMA-
FDA

★ CTA/IND approval

★ Conditional approval
& launch

★ Filing for
approval

CTA-IND filing


Pivotal global Phase 2-3 trial (~400 patients)

Manufacturing for trial supply,
scale-up for commercial supply

Conditional MA or MA Filing

Blockbuster potential & rapid growth



Blockbuster status of total sales expected by 2031-2032





Individual product sales on left-hand scale, total sales on right-hand scale

Preclinical programmes and non-pharmaceutical programmes

Pharmaceutical pipelines

Programme	Indication	Screening	Formulation	<i>In vitro</i>	<i>In vivo</i>
Muc1-P	Paediatric oral mucositis				
Muc2	Oesophagus mucositis				

Non-pharmaceutical products

Product	Function	Prototype	Dossier prep	Registration	Distribution
ANOXY Serum	Daily dermal protection				
ANOXY Balm	Daily scalp protection				

Experienced UK management team and Board



Ningfeng Fiona Li

MD PhD MSc

Co-Founder, CEO, CSO

Medical doctor specialised in radiation oncology, PhD scientist in cancer biology, serial entrepreneur in oncology drug discovery and development.

Management

Board



Hilary Birrell

BSc

Head of Clinical Operations

Clinical Research Professional with 35 years of experience in Clinical Trial Operations across multiple areas of healthcare.

Management

Board



Wills Hughes-Wilson

Non-Executive Director

Mereo BioPharma executive, has 20+ years' experience in biopharma leadership, specializing in strategic market pathways and commercial delivery.

Board



Peter McGowan

ACCA

CFO

Accountant with over 30 years of experience in both public and private companies, spanning multiple sectors, with a specialism in life sciences and tech.

Management



Austin Smith

MD, DPhm

Deputy Medical Officer

Highly experienced medical oncologist with proven track record in managing and supporting clinical trials and medical affairs.

Management



Emma Palmer Foster

MA, MBA

BD & IR Manager

Proven track record on corporate and financial strategy, investor relations and financial communications. Ex-senior equity analyst in life science banking industry.

Management



Gary Bower

BSc

Head of Clinical Development

Chemistry by training, experienced in biotech project management and clinical development management.

Management



Joseph Irwin

MSc, MRSB, FTOPRA, FRSM, FRSS FZS

Regulatory Advisor

Highly experienced regulatory professional, leading on European Regulatory Agency interactions and International Regulatory Affairs.

Management




Dawn Adkin

PhD BPharm

CMC Advisor

Proven senior manager with 8+ years at AstraZeneca, skilled pharmaceutical CMC consultant specialised in small molecule pharmaceuticals.

Management



Innovate for a better life living with cancer

Contact

Ningfeng Fiona Li, CEO
fiona.li@vasodynamics.co.uk

